Ribociclib 200Mg Oral Tablet clinical trials

Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

This study looks at a new way to treat women with a certain type of early breast cancer that's considered 'intermediate risk'. It compares a drug called ribociclib plus hormone therapy to standard chemotherapy, to see if the new approach works better.